GR3006506T3 - - Google Patents

Info

Publication number
GR3006506T3
GR3006506T3 GR920402654T GR920402654T GR3006506T3 GR 3006506 T3 GR3006506 T3 GR 3006506T3 GR 920402654 T GR920402654 T GR 920402654T GR 920402654 T GR920402654 T GR 920402654T GR 3006506 T3 GR3006506 T3 GR 3006506T3
Authority
GR
Greece
Prior art keywords
chloride
histidine
mixtures
ionic strength
factor viii
Prior art date
Application number
GR920402654T
Other languages
Greek (el)
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22354487&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR3006506(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GR3006506T3 publication Critical patent/GR3006506T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
GR920402654T 1987-10-29 1992-12-10 GR3006506T3 (OSRAM)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11431487A 1987-10-29 1987-10-29

Publications (1)

Publication Number Publication Date
GR3006506T3 true GR3006506T3 (OSRAM) 1993-06-30

Family

ID=22354487

Family Applications (1)

Application Number Title Priority Date Filing Date
GR920402654T GR3006506T3 (OSRAM) 1987-10-29 1992-12-10

Country Status (8)

Country Link
EP (1) EP0314095B1 (OSRAM)
JP (1) JP2544968B2 (OSRAM)
AT (1) ATE83155T1 (OSRAM)
AU (1) AU622133B2 (OSRAM)
CA (1) CA1329760C (OSRAM)
DE (1) DE3876600T2 (OSRAM)
ES (1) ES2053676T3 (OSRAM)
GR (1) GR3006506T3 (OSRAM)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2097120T3 (es) * 1989-07-24 1997-04-01 Bayer Ag Estabilizacion de proteinas altamente purificadas.
DE4001451A1 (de) * 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
DE4111393A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
US5288853A (en) * 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
US5399670A (en) * 1992-04-30 1995-03-21 Alpha Therapeutic Corporation Solubilization and stabilization of factor VIII complex
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
US6288030B1 (en) * 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
US5514781A (en) * 1994-04-11 1996-05-07 Bayer Corporation Use of azoles as virucidal agents in solutions of biologically active proteins
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
GB9501040D0 (en) * 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
US7253262B2 (en) 1995-01-19 2007-08-07 Quandrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US7244824B2 (en) 1995-01-19 2007-07-17 Quadrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
EP1561469A1 (en) * 1997-04-28 2005-08-10 Eli Lilly & Company Activated Protein C Formulations
TR199902631T2 (xx) * 1997-04-28 2000-01-21 Eli Lilly And Company Aktive C proteinin i�lenmesi i�in geli�tirilmi� y�ntemler
ES2179414T3 (es) * 1997-11-22 2003-01-16 Roche Diagnostics Gmbh Procedimiento mejorado de estabilizacion de proteinas.
EP2921180B1 (en) 1999-02-22 2019-08-14 University of Connecticut Albumin-free factor VIII formulations
US7204981B2 (en) 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
CA2410567A1 (en) 2000-05-24 2001-11-29 Eli Lilly And Company Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
HUP0402315A3 (en) 2001-12-21 2009-03-30 Novo Nordisk Healthcare Ag Liquid composition of factor vii polypeptides
CN1671410B (zh) 2002-06-21 2010-05-12 诺和诺德医疗保健公司 因子ⅶ多肽的稳定化固体组合物
AU2003251906B2 (en) * 2002-07-12 2008-12-04 Medarex, Inc. Methods and compositions for preventing oxidative degradation of proteins
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
JP2007534633A (ja) * 2003-11-10 2007-11-29 アライバ−プロメティック インコーポレイティド ヒト・アルファ１−抗トリプシン製剤
ATE507822T1 (de) 2003-12-19 2011-05-15 Novo Nordisk Healthcare Ag Stabilisierte zusammensetzungen von faktor-vii- polypeptiden
EP1854478A1 (en) * 2006-05-12 2007-11-14 Cytos Biotechnology AG Nicotine-carrier vaccine formulation
MX2009011367A (es) * 2007-04-26 2010-03-22 Bayer Healthcare Llc Estabilizacion de soluciones liquidas de proteina recombinante para el almacenamiento congelado.
MX339060B (es) 2008-11-07 2016-05-09 Baxter Int Formulaciones del factor viii.
CN103282045A (zh) * 2010-12-16 2013-09-04 诺沃—诺迪斯克有限公司 因子viii水溶液
KR102276161B1 (ko) 2011-10-25 2021-07-14 프로테나 바이오사이언시즈 리미티드 항체 제형 및 방법
EP2882457A1 (en) * 2012-08-13 2015-06-17 Novo Nordisk A/S Liquid factor viii formulations
CA3004145A1 (en) * 2015-11-05 2017-05-11 Novo Nordisk A/S Fviii formulation
EP3694322B1 (en) 2017-10-09 2024-07-03 Terumo BCT Biotechnologies, LLC Lyophilization container and method of using same
WO2020185916A1 (en) 2019-03-14 2020-09-17 Terumo Bct Biotechnologies, Llc Lyophilization container fill fixture, system and method of use
CN114072420B (zh) 2019-07-04 2024-06-11 康诺贝林伦瑙有限公司 用于增加凝血因子viii的体外稳定性的截短的血管性血友病因子(vwf)
EP4240757A2 (en) 2020-11-09 2023-09-13 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3237512A1 (de) * 1982-10-09 1984-04-12 Behringwerke Ag, 3550 Marburg Verfahren zur pasteurisierung von antihaemophilem kryopraezipitat (ahk) und danach hergestelltes antihaemophiles kryopraezipitat
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
DE3609431A1 (de) * 1986-03-20 1987-09-24 Biotest Pharma Gmbh Verfahren zur herstellung eines den blutgerinnungsfaktor viii enthaltenden, sterilen praeparates

Also Published As

Publication number Publication date
ATE83155T1 (de) 1992-12-15
ES2053676T3 (es) 1994-08-01
JP2544968B2 (ja) 1996-10-16
JPH01149733A (ja) 1989-06-12
CA1329760C (en) 1994-05-24
AU2452088A (en) 1989-05-04
EP0314095B1 (en) 1992-12-09
DE3876600T2 (de) 1993-04-15
AU622133B2 (en) 1992-04-02
DE3876600D1 (de) 1993-01-21
EP0314095A1 (en) 1989-05-03

Similar Documents

Publication Publication Date Title
GR3006506T3 (OSRAM)
GR3004891T3 (en) Plasma and recombinant protein formulations in low ionic strength media
AU610636B2 (en) Stabilised human protein preparations
HUT72558A (en) Defective adenovirus vectors and use thereof in gene therapy
IL65565A0 (en) Expression of the crystal protein of bacillus thuringiensis in e.coli
AU631681B2 (en) Radiolabeled anticoagulant peptides
BG103968A (en) Pharmaceutical antiviral composition containing glycirricinic acid and at least one protein with antiviral activity
AU3662593A (en) Pulmonary surfactant protein fragments
AU561590B2 (en) Stable composition of fibronectin
IL95863A0 (en) Anticoagulant peptides and compositions containing them
IL85189A (en) Beta-alkyl substituted melatonins,their preparation and pharmaceutical compositions containing them
AU4588089A (en) Anticoagulant peptides
PT80221A (en) Improved process for preparing benzamide derivatives useful as anticonvulsant agents
AU2817589A (en) Amino anthracenediones-bis platinum complexes, useful as antitumoral agents
EP0279633A3 (en) Anticonvulsant agents
AU2323984A (en) Recombinant dna expression vectors useful in bacillus
AU2323992A (en) Sequence for stabilizing proteins in bacteria protein stabilization sequence
DE3674971D1 (en) P-acylaminobenzamide.
BR9407357A (pt) Novos tripeptideos utilizáveis em terapia cns e imune
AU1507300A (en) Pharmaceutical compositions containing proteins
AU1879097A (en) Fragments of cr1 and their use
ZA889413B (en) Amino anthracenediones-bis platinum complexes,useful as antitumoral agents
AU5178593A (en) Protein fragments of the (pectinatus) bacterium
ZA902869B (en) Novel peptides,and antidementia agents containing the same
HU910063D0 (en) Process for the production of preparations containing synergetic combination of active agents of natural origin, usable for selective decreasing of blood lipoids